Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II concurrent ipilimumab, nivolumab, and radiotherapy for advanced non-small cell lung cancer
jRCTs021220003Phase 2Active, not recruiting
- Sponsor
- North East Japan Study Group
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoint: Objective response rate. Started Aug 2022; status: active, not recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs021220003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021220003.